Medtronic Takes Aim At Implantable Device Infections with TYRX Buy
This article was originally published in The Gray Sheet
Executive Summary
The $160 million cash acquisition fits with the firm’s efforts to fashion itself into a health care services and solutions company, rather than pure device firm. TYRX makes anti-bacterial envelopes for implanted devices, and has FDA clearances with cardiac implantable electronic devices and spinal cord neurostimulators.